Additional anti-myeloma effects of Selinexor occur through reactivation of tumor suppressor proteins (TSPs) such as p53, sensitization of the glucocorticoid receptor to Dexamethasone, inhibition of the mTOR pathway, and retention of inhibitor of NF-κB (lκB) [66,67,68]. This evidence concerns the gene NFKB1 and plasma cell myeloma.